Research & Development
AstraZeneca secures EU approval for Calquence combo as first-line treatment in mantle cell lymphoma
6 May 2025 - Biopharmaceutical company AstraZeneca PLC (LSE: AZN) (STO: AZN) (Nasdaq: AZN) announced on Tuesday that it has received European Commission approval for Calquence (acalabrutinib) in combi...
Bavarian Nordic secures USD143.6m US government contract for freeze-dried smallpox/mpox vaccine supply
6 May 2025 - Denmark-based vaccines company Bavarian Nordic A/S (CPH:BAVA) announced on Tuesday that the US Biomedical Advanced Research and Development Authority (BARDA) has exercised contract option...
Phanes Therapeutics doses first patient in peluntamig-atezolizumab combination clinical study
6 May 2025 - Phanes Therapeutics Inc, a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced on Monday that the first patient has been dosed in th...
Beijing Tide's AT2R antagonist TRD205 advances to Phase II trial in chronic post-surgical neuropathic pain
6 May 2025 - Beijing Tide Pharmaceutical Co Ltd, a subsidiary of China-based Sino Biopharmaceutical Limited (HK:1177), announced on Monday that it has achieved a milestone in developing its first-in-c...
FDA grants interchangeability status to SELARSDI from Alvotech and Teva
5 May 2025 - Biotech company Alvotech S.A. (NASDAQ:ALVO) and Teva Pharmaceuticals, a US affiliate of Israel-based pharmaceutical company Teva Pharmaceutical Industries Ltd (NYSE:TEVA) (TASE:TEVA), on ...
Pykus Therapeutics' PYK-2101 achieves positive interim clinical trial results
5 May 2025 - US-based pharmaceutical company Pykus Therapeutics Inc announced on Friday the presentation of positive clinical data from its ongoing pilot study evaluating the use of its proprietary, l...